Key Facts About Medicare Part D Enrollment, Premiums, and Cost Sharing in 2021 June 8, 2021 Issue Brief The Medicare Part D program provides an outpatient prescription drug benefit to older adults and people with long-term disabilities in Medicare who enroll in private plans, including stand-alone drug plans and Medicare Advantage drug plans. This analysis provides the latest data about Part D enrollment, premiums, and cost sharing in 2021 and trends over time.
Two-Thirds of the Public Say the U.S. Should Play a Major Role in Distributing COVID-19 Vaccines Globally, But Not Most Republicans June 3, 2021 News Release With increased attention to the global need for COVID-19 vaccines and the Biden administration’s announcement today about how it plans to distribute the first portion of the 80 million doses it will share by the end of this month, the latest KFF Health Tracking Poll finds that two-thirds of the…
KFF Health Tracking Poll – May 2021: Prescription Drug Prices Top Public’s Health Care Priorities June 3, 2021 Poll Finding The latest KFF Health Tracking Poll explores the public’s views on the U.S. role in distributing COVID vaccines to other countries, health care priorities for Congress, prescription drug regulations and price negotiations, and affordability changes in the COVID-19 relief bill.
How Might Current Federal Drug Pricing Proposals Impact Medicaid? May 24, 2021 Blog Although attention in current federal actions is largely focused on Medicare and private insurance drug prices, federal legislation also has been recently introduced or enacted that would affect Medicaid prescription drug policy.
A New Analysis Takes a Closer Look at Online Contraception Platforms Amid the Pandemic May 18, 2021 News Release Even prior to the COVID-19 pandemic, hormonal contraception became more accessible to many outside of traditional clinical settings through websites or apps that offer contraception via telehealth. To better understand this emerging method of contraceptive access, a new KFF analysis provides a deeper look at telecontraception platforms, offering insights into…
Potential Implications of Policy Changes in Medicaid Drug Purchasing May 4, 2021 Issue Brief This brief examines how leading federal and state policy options related to changes in Medicaid Drug Rebate Program (MDRP), drug pricing, and payment and management of the Medicaid prescription drug would affect state and federal governments as well as private industry (including drug manufacturers, managed care organizations, and pharmacies).
Moving the Needle on Prescription Drug Costs: Using the Innovation Center and Other Demonstration Authority March 25, 2021 Issue Brief This brief examines how the CMS Innovation Center (also known as CMMI) and Section 402 demonstration authority could become pathways for the Biden Administration to implement policy changes related to prescription drug costs.
A Status Report on Prescription Drug Policies and Proposals at the Start of the Biden Administration February 11, 2021 Issue Brief This brief provides a status update on prescription drug final rules advanced by the Trump Administration in its final months related to Medicare, importation, and 340B pricing for insulin and epinephrine, and an overview of key drug pricing proposals related to Medicare and prescription drug prices generally that were voted on but not enacted in the previous Congress that may return to the forefront of health policy discussions in the coming years.
How Can Trump Administration Regulations Be Reversed? January 29, 2021 Issue Brief With the inauguration of President Biden and Democrats holding a slim majority in Congress, policymakers are likely to consider whether and how to reverse various health policy regulations issued by the Trump Administration.
Get Ready for a Lot of Biden Executive Orders on Health Care January 7, 2021 Perspective In this column for the JAMA Health Forum, Larry Levitt explores what President-elect Biden might do to advance his health care vision both through legislation and through executive orders and waivers and demonstrations.